Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Cardiomyopathy, Hypertrophic, Familial
Welcome,
Profile
Billing
Logout
1 Company
1 Product
1 Product
0 Mechanisms of Action
0 Trials
11 News
||||||||||
Trial termination:
Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure
(clinicaltrials.gov) - Aug 31, 2017
P2
, N=35, Terminated,
Sponsor: Heart Metabolics Limited
Recruiting --> Terminated; Lack of Efficacy
|
|||||||||
eleclazine
(GS-6615) /
Gilead
Trial termination:
LIBERTY-HCM: Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
(clinicaltrials.gov) - Feb 28, 2017
P2/3
, N=172, Terminated,
Sponsor: Gilead Sciences
Recruiting --> Terminated; Lack of Efficacy Active, not recruiting --> Terminated
||||||||||
Trial primary completion date:
Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure
(clinicaltrials.gov) - Feb 17, 2017
P2
, N=33, Recruiting,
Sponsor: Heart Metabolics Limited
Active, not recruiting --> Terminated Trial primary completion date: Feb 2017 --> Jul 2017
|||||
|||||
eleclazine
(GS-6615) /
Gilead
Enrollment closed, Trial primary completion date:
LIBERTY-HCM: Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
(clinicaltrials.gov) - Dec 28, 2016
P2/3
, N=172, Active, not recruiting,
Sponsor: Gilead Sciences
Trial primary completion date: Feb 2017 --> Jul 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jan 2017
|
|||||||||
New P2 trial:
Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure
(clinicaltrials.gov) - Aug 11, 2016
P2
, N=33, Recruiting,
Sponsor: Heart Metabolics Limited
||||
||||||
eleclazine
(GS-6615) /
Gilead
Trial primary completion date:
LIBERTY-HCM: Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
(clinicaltrials.gov) - Jul 19, 2016
P2/3
, N=180, Recruiting,
Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jan 2017 Trial primary completion date: Jan 2017 --> Jul 2017
||||
||||||
eleclazine
(GS-6615) /
Gilead
Trial primary completion date:
LIBERTY-HCM: Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
(clinicaltrials.gov) - Sep 24, 2015
P2/3
, N=180, Recruiting,
Sponsor: Gilead Sciences
Trial primary completion date: Jan 2017 --> Jul 2017 Trial primary completion date: Jul 2016 --> Jan 2017
||||||
||||
eleclazine
(GS-6615) /
Gilead
Enrollment open:
LIBERTY-HCM: Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
(clinicaltrials.gov) - Jan 13, 2015
P2/3
, N=180, Recruiting,
Sponsor: Gilead Sciences
Trial primary completion date: Jul 2016 --> Jan 2017 Not yet recruiting --> Recruiting
||||||||||
eleclazine
(GS-6615) /
Gilead
New P2/3 trial:
LIBERTY-HCM: Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
(clinicaltrials.gov) - Nov 14, 2014
P2/3
, N=180, Not yet recruiting,
Sponsor: Gilead Sciences
||||||||||
Enrollment change:
Registry and Prevalence of Gene Mutation in Korean Patients With Familial Hypertrophic Cardiomyopathy
(clinicaltrials.gov) - Feb 16, 2014
P=N/A
, N=99, Completed,
Sponsor: Yonsei University
Not yet recruiting --> Recruiting N=250 --> 99
||||||||||
Trial completion:
Registry and Prevalence of Gene Mutation in Korean Patients With Familial Hypertrophic Cardiomyopathy
(clinicaltrials.gov) - Feb 16, 2014
P=N/A
, N=99, Completed,
Sponsor: Yonsei University
N=250 --> 99 Recruiting --> Completed